Integra LifeSciences [IART] vs Artivion [AORT] Detailed Stock Comparison
Integra LifeSciences
NASDAQ
Loading...
Artivion
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Integra LifeSciences wins in 9 metrics, Artivion wins in 10 metrics, with 0 ties. Artivion appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Integra LifeSciences | Artivion | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 66.48 | -127.19 | Artivion |
| Price-to-Book Ratio | 1.13 | 4.75 | Integra LifeSciences |
| Debt-to-Equity Ratio | 194.07 | 62.81 | Artivion |
| PEG Ratio | 5.98 | 0.79 | Artivion |
| EV/EBITDA | 9.60 | 47.16 | Integra LifeSciences |
| Profit Margin (TTM) | -30.87% | -4.43% | Artivion |
| Operating Margin (TTM) | 7.86% | 9.72% | Artivion |
| EBITDA Margin (TTM) | 7.86% | 9.72% | Artivion |
| Return on Equity | -38.92% | -5.02% | Artivion |
| Return on Assets (TTM) | 2.43% | 1.70% | Integra LifeSciences |
| Free Cash Flow (TTM) | $15.01M | $11.05M | Integra LifeSciences |
| 1-Year Return | -13.80% | 61.07% | Artivion |
| Price-to-Sales Ratio (TTM) | 0.72 | 4.93 | Integra LifeSciences |
| Enterprise Value | $2.94B | $2.15B | Integra LifeSciences |
| EV/Revenue Ratio | 1.81 | 5.30 | Integra LifeSciences |
| Gross Profit Margin (TTM) | 50.37% | 64.72% | Artivion |
| Revenue per Share (TTM) | $21 | $10 | Integra LifeSciences |
| Earnings per Share (Diluted) | $-6.54 | $-0.43 | Artivion |
| Beta (Stock Volatility) | 1.20 | 1.70 | Integra LifeSciences |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Integra LifeSciences vs Artivion Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Integra LifeSciences | -2.65% | -5.82% | 9.37% | 18.68% | -32.28% | -34.58% |
| Artivion | -3.81% | -6.42% | -7.18% | 41.61% | 73.27% | 44.94% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Integra LifeSciences | -13.80% | -66.94% | -67.70% | -53.11% | -22.41% | -17.25% |
| Artivion | 61.07% | 93.02% | 134.00% | 327.66% | 575.58% | 468.02% |
News Based Sentiment: Integra LifeSciences vs Artivion
Integra LifeSciences
News based Sentiment: MIXED
The month presented a mixed bag for Integra LifeSciences, with a stock price decline and negative price prediction offset by a clear growth strategy for 2026 and ongoing operational improvements. Analyst sentiment remains cautious, reflecting the ongoing challenges and uncertainties surrounding the company's turnaround.
Artivion
News based Sentiment: POSITIVE
Artivion delivered strong Q2 results and raised its full-year guidance, indicating positive momentum. While insider selling introduces a note of caution, the overall narrative remains positive due to the company's strong performance in specialized cardiology markets and promising product pipeline. The participation in the Morgan Stanley conference further supports investor interest.
Performance & Financial Health Analysis: Integra LifeSciences vs Artivion
| Metric | IART | AORT |
|---|---|---|
| Market Information | ||
| Market Cap | $1.17B | $1.92B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 1,202,480 | 405,400 |
| 90 Day Avg. Volume | 1,384,253 | 550,067 |
| Last Close | $15.06 | $40.70 |
| 52 Week Range | $11.06 - $27.13 | $21.97 - $45.07 |
| % from 52W High | -44.49% | -9.70% |
| All-Time High | $77.40 (Apr 26, 2021) | $45.07 (Aug 22, 2025) |
| % from All-Time High | -80.54% | -9.70% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.01% | 0.15% |
| Quarterly Earnings Growth | -0.01% | 0.15% |
| Financial Health | ||
| Profit Margin (TTM) | -0.31% | -0.04% |
| Operating Margin (TTM) | 0.08% | 0.10% |
| Return on Equity (TTM) | -0.39% | -0.05% |
| Debt to Equity (MRQ) | 194.07 | 62.81 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $13.33 | $8.91 |
| Cash per Share (MRQ) | $3.26 | $1.13 |
| Operating Cash Flow (TTM) | $70.89M | $19.65M |
| Levered Free Cash Flow (TTM) | $45.35M | $-12,697,875 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | $0.00 |
Valuation & Enterprise Metrics Analysis: Integra LifeSciences vs Artivion
| Metric | IART | AORT |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 66.48 | -127.19 |
| Forward P/E | 5.98 | 176.29 |
| PEG Ratio | 5.98 | 0.79 |
| Price to Sales (TTM) | 0.72 | 4.93 |
| Price to Book (MRQ) | 1.13 | 4.75 |
| Market Capitalization | ||
| Market Capitalization | $1.17B | $1.92B |
| Enterprise Value | $2.94B | $2.15B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.81 | 5.30 |
| Enterprise to EBITDA | 9.60 | 47.16 |
| Risk & Other Metrics | ||
| Beta | 1.20 | 1.70 |
| Book Value per Share (MRQ) | $13.33 | $8.91 |
Financial Statements Comparison: Integra LifeSciences vs Artivion
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | IART | AORT |
|---|---|---|
| Revenue/Sales | $415.61M | $112.97M |
| Cost of Goods Sold | $206.27M | $39.86M |
| Gross Profit | $209.33M | $73.11M |
| Research & Development | $27.00M | $7.06M |
| Operating Income (EBIT) | $-1.31M | $8.38M |
| EBITDA | $39.15M | $18.95M |
| Pre-Tax Income | $-530.95M | $3.48M |
| Income Tax | $-46.88M | $2.14M |
| Net Income (Profit) | $-484.07M | $1.35M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | IART | AORT |
|---|---|---|
| Cash & Equivalents | $239.10M | $37.69M |
| Total Current Assets | $1.11B | $287.30M |
| Total Current Liabilities | $918.45M | $51.94M |
| Long-Term Debt | $1.39B | $356.98M |
| Total Shareholders Equity | $1.52B | $294.25M |
| Retained Earnings | $914.62M | $-61.77M |
| Property, Plant & Equipment | $561.38M | $77.04M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | IART | AORT |
|---|---|---|
| Operating Cash Flow | $5.80M | $-17.94M |
| Capital Expenditures | $-28.92M | N/A |
| Free Cash Flow | $-40.18M | $-20.59M |
| Debt Repayment | $-15.24M | $-66,000 |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | IART | AORT |
|---|---|---|
| Shares Short | 7.19M | 1.09M |
| Short Ratio | 4.79 | 1.86 |
| Short % of Float | 0.15% | 0.03% |
| Average Daily Volume (10 Day) | 1,202,480 | 405,400 |
| Average Daily Volume (90 Day) | 1,384,253 | 550,067 |
| Shares Outstanding | 77.16M | 41.95M |
| Float Shares | 59.27M | 41.61M |
| % Held by Insiders | 0.14% | 0.05% |
| % Held by Institutions | 0.95% | 0.90% |
Dividend Analysis & Yield Comparison: Integra LifeSciences vs Artivion
| Metric | IART | AORT |
|---|---|---|
| Last 12-Month Dividend | N/A | $0.00 |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | $0.00 |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | $0.00 |
| Ex-Dividend Date | N/A | N/A |